# Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma

> **NCT05304481** · PHASE2 · RECRUITING · sponsor: **Lukas Biomedical Inc.** · enrollment: 95 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** ATL administration

## Key facts

- **NCT ID:** NCT05304481
- **Lead sponsor:** Lukas Biomedical Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-14
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-06-30
- **Target enrollment:** 95 (ESTIMATED)
- **Last updated:** 2025-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05304481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05304481, "Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05304481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*